Canada markets open in 1 hour 49 minutes

PFE Feb 2023 55.000 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
1.74000.0000 (0.00%)
As of 02:48PM EDT. Market open.
Full screen
Previous Close1.7400
Open1.8000
Bid0.0000
Ask0.0000
Strike55.00
Expire Date2023-02-17
Day's Range1.7200 - 1.9100
Contract RangeN/A
Volume41
Open Interest3.11k
  • Editor's Pick
    Yahoo Finance Video

    Axios sells itself to Cox Enterprises, Carlyle CEO to step down, CVS and Pfizer look to expand

    Yahoo Finance's Julie Hyman breaks down leading business headlines today regarding M&A activity and leadership changes.

  • Reuters

    UPDATE 1-EU regulator begins review of Pfizer-BioNTech's variant-adapted COVID shot

    The European Medicines Agency (EMA) has started a rolling review of a variant-adapted COVID-19 vaccine from Pfizer and BioNTech, it said on Tuesday. The so-called bivalent vaccine targets two strains of the SARS-CoV-2 virus behind COVID - the original strain first identified in China, and the Omicron offshoots BA.4/5 that are currently behind most cases in Europe. A rolling review means the EMA assesses the data as it becomes available, and the process continues until there is enough data for a formal marketing application.

  • Business Wire

    Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

    NEW YORK & SAINT-HERBLAIN, France, August 08, 2022--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524), to investigate the efficacy, safety and immunogenicity of their investigational Lyme disease vaccine candidate, VLA15.